You have full access to this article via your institution. To demonstrate the power of PCR–mediated recombination and provide an example of the general utility of the method, we constructed ...

The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Structural and functional analyses identify a new family of bifunctional cell-wall-targeting type VI secretion system (T6SS) effectors and a surface-charge-engineering strategy that expands T6SS ...

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

About ADI-001 ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 was granted Fast ...

Microcap Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17 million tax rebate from Canberra for R&D activities. The cell therapy tech developer now sits on a >$4M cash injection ...